{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:40:29Z","timestamp":1792032029116,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clbc.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,6,23]],"date-time":"2014-06-23T01:45:50Z","timestamp":1403487950000},"page":"468-474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit"],"prefix":"10.1016","volume":"14","author":[{"given":"Debora","family":"de Melo Gagliato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis L. Fontes","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2014.06.001_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1126\/science.1846706","article-title":"Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product","volume":"251","author":"Bottaro","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.clbc.2014.06.001_bib2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/jcb.10358","article-title":"HGF\/SF-met signaling in the control of branching morphogenesis and invasion","volume":"88","author":"Zhang","year":"2003","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.clbc.2014.06.001_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc1912","article-title":"Invasive growth: a MET-driven genetic programme for cancer and stem cells","volume":"6","author":"Boccaccio","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clbc.2014.06.001_bib5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1172\/JCI0215418","article-title":"Dysregulation of Met receptor tyrosine kinase activity in invasive tumors","volume":"109","author":"Danilkovitch-Miagkova","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clbc.2014.06.001_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clbc.2014.06.001_bib7","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.2011.40.3774","article-title":"Targeting the hepatocyte growth factor-cMET axis in cancer therapy","volume":"30","author":"Blumenschein","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.06.001_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.clbc.2014.06.001_bib9","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6","article-title":"Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family","volume":"82","author":"Olivero","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib10","first-page":"6272","article-title":"c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions","volume":"63","author":"Ma","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib11","doi-asserted-by":"crossref","first-page":"17198","DOI":"10.1073\/pnas.0407651101","article-title":"Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele","volume":"101","author":"Graveel","year":"2004","journal-title":"Proc Natl Acad Sci U\u00a0S A"},{"key":"10.1016\/j.clbc.2014.06.001_bib12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib13","first-page":"6417","article-title":"Gene amplification in gastric and esophageal adenocarcinomas","volume":"50","author":"Houldsworth","year":"1990","journal-title":"Cancer Res"},{"issue":"2 Suppl Pediatrics","key":"10.1016\/j.clbc.2014.06.001_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3171\/ped.2004.100.2.0187","article-title":"Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization","volume":"100","author":"Tong","year":"2004","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.clbc.2014.06.001_bib15","doi-asserted-by":"crossref","first-page":"20007","DOI":"10.1073\/pnas.0710052104","article-title":"Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma","volume":"104","author":"Beroukhim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2014.06.001_bib16","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.clbc.2014.06.001_bib17","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1073\/pnas.0508776103","article-title":"Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752","volume":"103","author":"Smolen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2014.06.001_bib18","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.canlet.2008.02.049","article-title":"c-Met gene amplification is associated with\u00a0advanced stage colorectal cancer and liver metastases","volume":"265","author":"Zeng","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clbc.2014.06.001_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1159\/000011898","article-title":"Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features","volume":"55","author":"Tsugawa","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2014.06.001_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E","article-title":"Expression of the c-Met\/HGF receptor in human breast carcinoma: correlation with tumor progression","volume":"74","author":"Beviglia","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib21","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1158\/0008-5472.CAN-10-0911","article-title":"Tyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cells","volume":"70","author":"Hochgrafe","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/bcr2617","article-title":"The Met oncogene and basal-like breast cancer: another culprit to watch out for?","volume":"12","author":"Gastaldi","year":"2010","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/ijc.20598","article-title":"C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2\/neu","volume":"113","author":"Lengyel","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2014.06.001_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.canlet.2005.08.007","article-title":"A\u00a0transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing","volume":"239","author":"Tengs","year":"2006","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clbc.2014.06.001_bib27","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clbc.2014.06.001_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2014.06.001_bib29","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1158\/0008-5472.CAN-10-0489","article-title":"HGF\/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors","volume":"70","author":"Shojaei","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib30","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib31","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","article-title":"Basal-like breast cancer: a critical review","volume":"26","author":"Rakha","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.06.001_bib32","doi-asserted-by":"crossref","first-page":"12909","DOI":"10.1073\/pnas.0810403106","article-title":"Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer","volume":"106","author":"Graveel","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2014.06.001_bib33","doi-asserted-by":"crossref","first-page":"12903","DOI":"10.1073\/pnas.0810402106","article-title":"Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer","volume":"106","author":"Ponzo","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2014.06.001_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s12032-013-0801-7","article-title":"Cytokeratin 5\/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer","volume":"31","author":"Inanc","year":"2014","journal-title":"Med Oncol"},{"issue":"1 Suppl","key":"10.1016\/j.clbc.2014.06.001_bib35","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1177\/1758834011422557","article-title":"c-MET as a potential therapeutic target and biomarker in cancer","volume":"3","author":"Sierra","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2014.06.001_bib36","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1158\/1541-7786.MCR-13-0042","article-title":"MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance","volume":"11","author":"Paulson","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/bjc.2012.335","article-title":"Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer","volume":"107","author":"Minuti","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2014.06.001_bib38","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-11-2830","article-title":"cMET and phospho-cMET protein levels in breast cancers and survival outcomes","volume":"18","author":"Raghav","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2014.06.001_bib39","first-page":"825","volume":"32","author":"Ai","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914001074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914001074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:12:41Z","timestamp":1761513161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820914001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1526820914001074"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2014.06.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}